New finance leaders appointed at Immuron (NASDAQ: IMRN)

Rhea-AI Filing Summary

Immuron Limited reported leadership changes effective 9 February 2026, with Mr Phillip Hains resigning as Chief Financial Officer and Company Secretary after serving since 2013. The company appointed Olga Smejkalova as Company Secretary and Aaron Laurita as Chief Financial Officer on the same date.

The announcement notes Ms Smejkalova will handle ASX Listing Rule communications and highlights both appointees’ governance, finance and commercial experience. The filing also reiterates Immuron’s focus on orally delivered targeted polyclonal antibodies and provides background on its Travelan product for travelers’ diarrhea.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of February 2026

Commission File Number: 001-38104

IMMURON LIMITED

(Name of Registrant)

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒      Form 40-F ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐      No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

IMMURON LIMITED

EXPLANATORY NOTE

Immuron Limited (the “Company”) published an announcement (the “Public Notices”) to the Australian Securities Exchange on February 9, 2026, titled:

99.1 Company Secretary/CFO Appointment/Resignation

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

1

EXHIBITS

Exhibit Number		Description
99.1		Company Secretary/CFO Appointment/Resignation

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	IMMURON LIMITED
Date: February 9, 2026	By:	/s/ Olga Smejkalova
		Olga Smejkalova
		Company Secretary

3

Exhibit 99.1

ASX Announcement

9 February 2026

Resignation/Appointment of Company Secretary and Chief Financial Officer

Immuron Limited (ASX: IMC; NASDAQ: IMRN) advises, in accordance with ASX Listing Rule 3.16.1, that Mr Phillip Hains has resigned as Chief Financial Officer and Company Secretary, effective 9 February 2026.

The Board thanks Mr Hains for his valuable contribution to the Company since 2013 and wishes him well in his future endeavours.

The Company is pleased to announce the appointment of Ms Olga Smejkalova as Company Secretary, effective 9 February 2026. In accordance with ASX Listing Rule 12.6, Ms Smejkalova will be the person responsible for communication with the ASX on Listing Rule matters. Ms Smejkalova brings extensive experience in corporate governance and compliance, and the Board looks forward to her contribution in this role.

The Company is also pleased to announce the appointment of Mr Aaron Laurita as Chief Financial Officer, effective 9 February 2026. Mr Laurita brings strong finance and commercial expertise, developed through his work across several sectors, and the Board looks forward to his contribution in this role.

This release has been authorised by the Directors of Immuron Limited.

COMPANY CONTACT:

Steven Lydeamore

Chief Executive Officer

steve@immuron.com

About Travelan®

Travelan® is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers’ diarrhea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan® is a purified tablet preparation of hyper-immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with traveler’s diarrhea. In Australia, Travelan® is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Traveler’s Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan® is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Traveler’s Diarrhea. In the U.S., Travelan® is sold as a dietary supplement for digestive tract protection.

About Immuron

Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.

Immuron Platform Technology

Immuron’s proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum. Immuron has the capability of producing highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine IgG can withstand the acidic environment of the stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal (GI) tract. Bovine IgG also possesses this unique ability to remain active in the human GI tract delivering its full benefits directly to the bacteria found there. The underlying nature of Immuron’s platform technology enables the development of medicines across a large range of infectious diseases. The platform can be used to block viruses or bacteria at mucosal surfaces such as the Gastrointestinal tract and neutralize the toxins they produce.

For more information visit: https://www.immuron.com.au/ and https://www.travelan.com

Sign up to Immuron’s Investor Hub: Here

FORWARD-LOOKING STATEMENTS:

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

FAQ

What leadership changes did Immuron (IMRN) announce in this Form 6-K?

Immuron announced that Phillip Hains resigned as Chief Financial Officer and Company Secretary, effective 9 February 2026. The company simultaneously appointed Olga Smejkalova as Company Secretary and Aaron Laurita as Chief Financial Officer, signaling a full transition of its finance and corporate secretariat roles.

Who is Immuron’s new Company Secretary and what is her role?

Immuron appointed Olga Smejkalova as Company Secretary effective 9 February 2026. She is responsible for communication with the Australian Securities Exchange on Listing Rule matters and brings extensive corporate governance and compliance experience to support the company’s regulatory and board processes.

Who is Immuron’s new Chief Financial Officer (IMRN)?

Immuron named Aaron Laurita as Chief Financial Officer effective 9 February 2026. The company states he brings strong finance and commercial expertise developed across several sectors, supporting Immuron’s financial management and strategic planning as it advances its biopharmaceutical development and commercialization activities.

What is Immuron’s Travelan product and where is it sold?

Travelan is an orally administered preparation of hyper-immune bovine antibodies designed to reduce the risk of travelers’ diarrhea. It is listed as a therapeutic good in Australia, a licensed natural health product in Canada, and is sold in the United States as a dietary supplement for digestive protection.

What is Immuron Limited’s core business focus (NASDAQ: IMRN)?

Immuron is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies. Its platform uses hyper-immune bovine colostrum to produce immunoglobulins aimed at inflammatory-mediated and infectious diseases, particularly in the gastrointestinal tract and other mucosal surfaces.

What technology underpins Immuron’s antibody platform?

Immuron’s platform is based on polyclonal IgG antibodies derived from engineered hyper-immune bovine colostrum. These antibodies can withstand stomach acid and digestive enzymes, allowing them to remain active in the gastrointestinal tract and target a range of enteric pathogens and their toxins locally.